Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Methimazole in Glioblastoma: NCT05607407 Clinical Landscape Report 2026
16 October 2026
NCT05607407 clinical landscape for Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
CHM-1101 in Glioblastoma Multiforme: NCT05627323 Clinical Landscape Report 2026
16 October 2026
NCT05627323 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
11C-methionine in Glioblastoma Multiforme: NCT05608395 Clinical Landscape Report 2026
16 October 2026
NCT05608395 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Bevacizumab in Glioblastoma Multiforme: NCT05611645 Clinical Landscape Report 2026
16 October 2026
NCT05611645 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
CARv3-TEAM-E T cells(Massachusetts General Hospital) in Glioblastoma Multiforme: NCT05660369 Clinical Landscape Report 2026
16 October 2026
NCT05660369 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
QRL-101 in Amyotrophic Lateral Sclerosis: NL-OMON53647 Clinical Landscape Report 2026
16 October 2026
NL-OMON53647 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
QRL-201 in Amyotrophic Lateral Sclerosis: NCT05633459 Clinical Landscape Report 2026
16 October 2026
NCT05633459 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Temozolomide in Marijuana Abuse: NCT05629702 Clinical Landscape Report 2026
16 October 2026
NCT05629702 clinical landscape for Marijuana Abuse: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Azeliragon in Glioblastoma Multiforme: NCT05635734 Clinical Landscape Report 2026
16 October 2026
NCT05635734 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Sintilimab in Recurrent Glioblastoma: NCT05638451 Clinical Landscape Report 2026
16 October 2026
NCT05638451 clinical landscape for Recurrent Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
GD2 chimeric antigen receptor-expressing peripheral blood T cells(Royal Adelaide Hospital) in Astrocytoma: ACTRN12622001514796 Clinical Landscape Report 2026
16 October 2026
ACTRN12622001514796 clinical landscape for Astrocytoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Temozolomide in Glioblastoma: NCT05664464 Clinical Landscape Report 2026
16 October 2026
NCT05664464 clinical landscape for Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.